An observational study in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-20.
Sponsored by Boehringer Ingelheim · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 5th largest by enrollment of the 34 observational ones that give a count, is one of 6 that started in 2016, is one of 34 observational ones, and was the 108th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Australia, Canada and 3 more countries
Ages 18+
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 48 more countries
Ages 18+
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 344,995 is above the median of 300 across 1,742 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 302 across the 96 interventional studies, 10,286 across the 34 observational. Of the 125 that completed or were terminated, 109 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,304 studies on the registry; 61 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05882071Boehringer IngelheimNon-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to assess the risk of urinary tract malignancies in patients initiating empagliflozin (free or fixed dose combination) compared to patients initiating a dipeptidyl peptidase-4 (DPP-4) inhibitor.
This is an observational, comparative, cohort safety study based on European healthcare databases and includes databases from the UK, Finland, and Sweden.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with Type 2 diabetes mellitus (T2D) initiating (first purchase/prescription) empagliflozin (study drug), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2021 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from Clinical Practice Research Datalink (CPRD) (General practitioner Online Data \[GOLD\], and Aurum) in the United Kingdom (UK).
Drug: empagliflozin
Participants with T2D initiating (first purchase/prescription) a dipeptidyl peptidase-4 inhibitor (DPP-4i) (comparator), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2021 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from CPRD (General practitioner Online Data \[GOLD\], and Aurum) in the UK.
Drug: DPP-4 inhibitors
Participants with T2D initiating (first purchase/prescription) empagliflozin (study drug), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2020 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from the nationwide registers in Sweden.
Drug: empagliflozin
Participants with T2D initiating (first purchase/prescription) a dipeptidyl peptidase-4 inhibitor (DPP-4i) (comparator), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2020 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from the nationwide registers in Sweden.
Drug: DPP-4 inhibitors
Participants with T2D initiating (first purchase/prescription) empagliflozin (study drug), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2020 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from the nationwide registers in Finland.
Drug: empagliflozin
Participants with T2D initiating (first purchase/prescription) a dipeptidyl peptidase-4 inhibitor (DPP-4i) (comparator), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2020 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from the nationwide registers in Finland.
Drug: DPP-4 inhibitors
empagliflozin
DPP-4 inhibitors
Occurrence of Urinary Tract Cancer
Occurrence of urinary tract cancer, which include malignant neoplasm and carcinoma in situ of the urinary tract, is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.
Time frame: From 181 days after index date until the occurrence of a censoring event or cancer outcome event. Up to 6 (Sweden/Finland) or 7 years (UK).
Occurrence of Bladder Cancer
Occurrence of bladder cancer, malignant and carcinoma in situ, is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.
Time frame: From 181 days after index date until the occurrence of a censoring event or cancer outcome event. Up to 6 (Sweden/Finland) or 7 years (UK).
Occurrence of Renal Cancer
Occurrence of malignant renal cancer is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.
Time frame: From 181 days after index date until the occurrence of a censoring event or cancer outcome event. Up to 6 (Sweden/Finland) or 7 years (UK).
This was a non-interventional, comparative, cohort-based Post-authorisation-safety study (PASS) to assess the risk of urinary tract malignancies in patients affected by type 2 diabetes mellitus initiating empagliflozin or dipeptidyl peptidase-4 inhibitor (DPP-4i) between 1-Aug-2014 and 31-Dec-2021 in the United Kingdom (UK), Sweden, and Finland.
| Milestone | Empagliflozin Initiators - UK | DPP4-i Initiators - UK | Empagliflozin Initiators - Sweden | DPP4-i Initiators - Sweden | Empagliflozin Initiators - Finland | DPP4-i Initiators - Finland |
|---|---|---|---|---|---|---|
| Started | 27410 | 123334 | 35954 | 73623 | 21942 | 62732 |
| Completed | 27410 | 123334 | 35954 | 73623 | 21942 | 62732 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Occurrence of urinary tract cancer, which include malignant neoplasm and carcinoma in situ of the urinary tract, is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.
| Events per 1000 patient years | Empagliflozin Initiators - UK, PS-matched | DPP4-i Initiators - UK, PS-matched | Empagliflozin Initiators - Sweden, PS-matched | DPP4-i Initiators - Sweden, PS-matched | Empagliflozin Initiators - Finland, PS-matched | DPP4-i Initiators - Finland, PS-matched | Empagliflozin Initiators - All Countries, PS-matched | DPP4-i Initiators - All Countries, PS-matched |
|---|---|---|---|---|---|---|---|---|
| Occurrence of Urinary Tract Cancer | 0.73 (0.46 to 1.16) | 1.07 (0.84 to 1.37) | 1.34 (0.95 to 1.89) | 1.52 (1.13 to 2.05) | 1.27 (0.86 to 1.87) | 1.49 (1.13 to 1.96) | 1.10 (0.88 to 1.38) | 1.29 (1.11 to 1.51) |
Occurrence of bladder cancer, malignant and carcinoma in situ, is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.
| Events per 1000 patient years | Empagliflozin Initiators - UK, PS-matched | DPP4-i Initiators - UK, PS-matched | Empagliflozin Initiators - Sweden, PS-matched | DPP4-i Initiators - Sweden, PS-matched | Empagliflozin Initiators - Finland, PS-matched | DPP4-i Initiators - Finland, PS-matched | Empagliflozin Initiators - All Countries, PS-matched | DPP4-i Initiators - All Countries, PS-matched |
|---|---|---|---|---|---|---|---|---|
| Occurrence of Bladder Cancer | 0.45 (0.25 to 0.81) | 0.67 (0.49 to 0.90) | 0.92 (0.61 to 1.40) | 1.03 (0.71 to 1.48) | 0.51 (0.27 to 0.94) | 0.64 (0.42 to 0.98) | 0.63 (0.47 to 0.85) | 0.74 (0.6 to 0.91) |
Occurrence of malignant renal cancer is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.
| Events per 1000 patient years | Empagliflozin Initiators - UK, PS-matched | DPP4-i Initiators - UK, PS-matched | Empagliflozin Initiators - Sweden, PS-matched | DPP4-i Initiators - Sweden, PS-matched | Empagliflozin Initiators - Finland, PS-matched | DPP4-i Initiators - Finland, PS-matched | Empagliflozin Initiators - All Countries, PS-matched | DPP4-i Initiators - All Countries, PS-matched |
|---|---|---|---|---|---|---|---|---|
| Occurrence of Renal Cancer | 0.24 (0.11 to 0.54) | 0.34 (0.22 to 0.52) | 0.42 (0.22 to 0.78) | 0.50 (0.29 to 0.84) | 0.76 (0.46 to 1.26) | 0.82 (0.57 to 1.19) | 0.45 (0.32 to 0.65) | 0.51 (0.4 to 0.65) |
Collected over This study used secondary data only. Hence, reporting of adverse reactions was not required nor possible.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Empagliflozin Initiators - UK | — | — | — |
| DPP4-i Initiators - UK | — | — | — |
| Empagliflozin Initiators - Sweden | — | — | — |
| DPP4-i Initiators - Sweden | — | — | — |
| Empagliflozin Initiators - Finland | — | — | — |
| DPP4-i Initiators - Finland | — | — | — |
Study population: population before propensity score-matching.
| Age, Continuous(Years) | Empagliflozin Initiators - UK | DPP4-i Initiators - UK | Empagliflozin Initiators - Sweden | DPP4-i Initiators - Sweden | Empagliflozin Initiators - Finland | DPP4-i Initiators - Finland | Total |
|---|---|---|---|---|---|---|---|
| Mean | 56.51 ± 10.96 | 63.50 ± 13.24 | 62.75 ± 11.18 | 66.65 ± 12.66 | 60.11 ± 11.84 | 66.04 ± 13.42 | 63.78 ± 12.93 |
| Sex: Female, Male(Participants) | Empagliflozin Initiators - UK | DPP4-i Initiators - UK | Empagliflozin Initiators - Sweden | DPP4-i Initiators - Sweden | Empagliflozin Initiators - Finland | DPP4-i Initiators - Finland | Total |
|---|---|---|---|---|---|---|---|
| Female | 16922 | 72124 | 24825 | 44352 | 13048 | 34233 | 205504 |
| Male | 10488 | 51210 | 11129 | 29271 | 8894 | 28499 | 139491 |
| Race and Ethnicity Not Collected(Participants) | Empagliflozin Initiators - UK | DPP4-i Initiators - UK | Empagliflozin Initiators - Sweden | DPP4-i Initiators - Sweden | Empagliflozin Initiators - Finland | DPP4-i Initiators - Finland | Total |
|---|---|---|---|---|---|---|---|
| Count of participants | — | — | — | — | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Nov 2016 to primary completion in Mar 2024, 87 months.
Results were first posted in Mar 2025, 1 year after primary completion.
Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's 87 months is above that.
Counting every sponsor, half of 603 studies reached it within 32 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.